Jung Won Shin
Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector.
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.
Latest From Jung Won Shin
Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
Ildong has become the latest Korean pharma firm to start developing an oral COVID-19 drug in the country, potentially competing with Merck and Pfizer’s candidates which are now under approval review locally. The latest co-development deal is also set to expand the market prospects for the antiviral's Japanese originator.
Notable third-quarter developments at major Korean pharma firms included the domestic reimbursement of Yuhan’s Leclaza, the approval of Hanmi’s Rolontis and SK Bioscience's approval filing for Novavax's COVID-19 vaccine for supply in the country, a roundup of results by Scrip shows.
Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.
SK Biopharmaceuticals advances into the Greater China market via a CNS focused Chinese company with China’s 6 Dimensions Capital, backed by a large series A financing. It has also licensed its CNS therapy pipeline to the new Chinese operation.